Seeing How RNA Is Regulated in Tissue Without Sequencing: Nanoneedle Arrays Map Molecules in Brain and Biopsy Sections

Tissue is more than a collection of cells; where the same molecule appears and which cells produce it often determine how development proceeds and may also influence the course of disease. Spatial transcriptomics has therefore advanced rapidly, but it often requires complex sample processing, RNA amplification, and sequencing. A study published in *Nature Biomedical Engineering* proposes another approach: using nanoneedles to “fish out” RNA from fresh sections, then reconstructing its location within the tissue through fluorescent signals.

The platform, called Spectrum-FISH, arranges vertical nanoprobes on a biochip. After the probes contact acute tissue sections, they capture intracellular molecules while preserving the spatial coordinates of each sampling location; researchers then identify the targets using multiplex fluorescence encoding and image decoding. The entire process does not rely on sequencing or require prior amplification of nucleic acid signals, and it can achieve subcellular-scale localization across large-area sections.

The platform measures more than messenger RNA. The research team also tracked microRNAs that regulate gene expression, as well as RNA carrying N6-methyladenosine (m6A) modifications. The latter two represent post-transcriptional layers of regulation that can affect RNA stability, translation, and degradation, but may not be directly visible using conventional methods that measure only the amount of gene transcription. In other words, the map depicts not only which genes are being read, but also how RNA is processed and managed after leaving the “production line.”

The researchers first demonstrated patterned mRNA distributions in developing mouse neural tissue, then applied the method to the distinctly layered olfactory bulb to examine the spatial heterogeneity of microRNAs and m6A-modified RNA. The results were cross-compared with in situ fluorescence hybridization, immunostaining, and bulk-sample measurements. The paper states that the platform’s sensitivity and spatial fidelity are comparable to those of existing spatial transcriptomics methods. These experiments remain primarily technical validation, and causal relationships between the observed molecular clusters and neural function have not yet been established.

The team also applied Spectrum-FISH to human colorectal biopsy tissue, showing that it can process clinically obtained samples. Principal investigator Peng Shi previously stated at a conference at City University of Hong Kong that the platform can also analyze fresh or processed human tissue; conference materials also said that each test costs less than US$10. However, publicly available information does not specify whether this estimate includes chip manufacturing, microscopic imaging, equipment depreciation, and labor, so it cannot be directly equated with the actual cost of hospital testing.

Eliminating sequencing could shorten the workflow and lower barriers to data processing, making the platform particularly suitable for developing spatial assays targeting known RNA markers. However, probe-based methods generally require targets to be selected in advance, and their ability to discover unknown transcripts differs from that of unbiased sequencing. The multiplexing limit of fluorescent signals, extraction efficiency across different tissues, batch consistency, and section quality may also affect the results. To advance toward disease stratification or prognostic assessment, the method still needs validation in more patients, across different diseases, and in independent laboratories, as well as evidence that it can provide clinical information beyond current pathology workflows.